CCR5 and acute myeloid leukemia: Seven months after presentation, AML relapsed, and the patient underwent allo-HSCT with CD34+ peripheral blood stem cells from an HLA-identical donor who had been screened for homozygosity for the CCR5 delta32 allele (CCR5 Δ32/Δ32).